Our COVID19 phase 2 clinical trial for our lead product, rhu-pGSN, has begun.

Share on facebook
Share on twitter
Share on linkedin

May, 2020: BioAegis ‘Inflammation Regulator’ Highlighted in CNBC Feature Story on COVID-19

BioAegis says its ‘inflammation regulator’ is best weapon to fight COVID-19

Monday, May 11, 2020 | By Barbara Booth

KEY POINTS:

  • BioAegis Therapeutics believes that its lead product, recombinant human plasma gelsolin therapy (rhu-pGSN), is a viable therapeutic option for patients suffering from severe lung injury due to Covid-19.

  • The private clinical stage company is awaiting FDA approval to accelerate their clinical trial of plasma gelsolin therapy on Covid-19 patients.

  • BioAegis discovered plasma gelsolin — an abundant, naturally occurring circulating protein found in the human body’s immune system — nearly two decades ago.

  • The company has built a portfolio of therapies around this unique anti-inflammatory to treat a wide range of conditions, including influenza, pneumonia, arthritis, Alzheimer’s, lupus, inflammatory bowel disease and multiple sclerosis.

“We’ve been studying this exact same condition — not with this particular virus, but with severe flu, severe pneumonia — for years, so we feel like we are in the perfect position to treat this disease.”

Dr. Susan Levinson, BioAegis CEO